Synthesis of enantiomerically pure 4-aryl-3,4-dihydropyrimidin-2(1H)-ones via enzymatic resolution: preparation of the antihypertensive agent (R)-SQ 32926

Tetrahedron Asymmetry

Volumn 11, Issue 7, 2000, Pages 1449-1453

  Schnell, Barbara ^a   Strauss, Ulrike T ^a   Verdino, Petra ^a   Faber, Kurt ^a   Kappe, C Oliver ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOCARBONYL 3,4 DIHYDRO 6 METHYL 4 (3 NITROPHENYL) 2(1H) OXOPYRIMIDINE 5 CARBOXYLIC ACID ISOPROPYL ESTER; 3,4 DIHYDRO 2(1H) PYRIMIDINONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; PYRIMIDINONE DERIVATIVE; SQ 32926; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; CIRCULAR DICHROISM; DRUG PURIFICATION; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVITY; ENZYME SPECIFICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 0034073769     PISSN: 09574166     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-4166(00)00081-1     Document Type: Article

References (26)

1. For a review on dihydropyrimidones of this type, see: Kappe, C. O. Tetrahedron 1993, 49, 6937-6963.
2. Atwal, K. S.; Rovnyak, G. C.; Kimball, D. S.; Floyd, D. M.; Moreland, S.; Swanson, B. N.; Gougoutas, J. Z.; Schwartz, J.; Smillie, K. M.; Malley, M. F. J. Med. Chem. 1990, 33, 2629-2635.
3. Nagarathanm, D.; Miao, S. W.; Lagu, B.; Chiu, G.; Fang, J.; Dhar, T. G. M.; Zhang, J.; Tyagarajan, S.; Marzabadi, M. R.; Zhang, F. Q.; Wong, W. C.; Sun, W. Y.; Tian, D.; Wetzel, J. M.; Forray, C.; Chang, R. S. L.; Broten, T. P.; Ransom, R. W.; Schorn, T. W.; Chen, T. B.; O'Malley, S.; Kling, P.; Schneck, K.; Bendesky, R.; Harrell, C. M.; Vyas, K. P.; Gluchowski, C. J. Med. Chem. 1999, 42, 4764-4777 and following papers in this series.
4. Mayer, T. U.; Kapoor, T. M.; Haggarty, S.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Science 1999, 286, 971-974.
5. Bruce, M. A.; Pointdexter, G. S.; Johnson, G. PCT Int. Appl. WO 98 33,791; Chem. Abstr. 1998, 129, 148989g.
6. Bruce, M. A.; Pointdexter, G. S.; Johnson, G. PCT Int. Appl. WO 98 33,791; Chem. Abstr. 1998, 129, 148989g.
7. Goldmann, S.; Stoltefuß, J.; Paessens, A.; Graef, E.; Lottmann, S. Ger. Offen. DE 19,817,262; Chem. Abstr. 1999, 131, 286535y.
8. Goldmann, S.; Stoltefuß, J.; Paessens, A.; Graef, E.; Lottmann, S. Ger. Offen. DE 19,817,262; Chem. Abstr. 1999, 131, 286535y.
9. Wichmann, J.; Adam, G.; Kolczewski, S.; Mutel, V.; Woltering, T. Bioorg. Med. Chem. Lett. 1999, 9, 1573-1576.
10. Atwal, K. S.; Swanson, B. N.; Unger, S. E.; Floyd, D. M.; Moreland, S.; Hedberg, A.; O'Reilly, B. C. J. Med. Chem. 1991, 34, 806-811.
11. Rovnyak, G. C.; Atwal, K. S.; Hedberg, A.; Kimball, S. D.; Moreland, S.; Gougoutas, J. Z.; O'Reilly, B. C.; Schwartz, J.; Malley, M. F. J. Med. Chem. 1992, 35, 3254-3263.
12. Grover, G. J.; Dzwonczyk, S.; McMullen, D. M.; Normadinam, C. S.; Sleph, P. G.; Moreland, S. J. J. Cardiovasc. Pharmacol. 1995, 26, 289-294.
13. Rovnyak, G. C.; Kimball, S. D.; Beyer, B.; Cucinotta, G.; DiMarco, J. D.; Gougoutas, J.; Hedberg, A.; Malley, M.; McCarthy, J. P.; Zhang, R.; Moreland, S. J. Med. Chem. 1995, 38, 119-129.
14. Kappe, C. O.; Uray, G.; Roschger, P.; Lindner, W.; Kratky, C.; Keller, W. Tetrahedron 1992, 48, 5473-5480.
15. Kleidernigg, O. P.; Kappe, C. O. Tetrahedron: Asymmetry 1997, 8, 2057-2067.
16. Lewandowski, K.; Murer, P.; Svec, F.; Fréchet, J. M. J. J. Comb. Chem. 1999, 1, 105-112.
17. In the corresponding DHP series the application of biocatalytic methods in order to obtain enantiomerically pure derivatives is well established: (a) Holdgrün, X. K.; Sih, C. J. Tetrahedron Lett. 1991, 32, 3465-3468. (b) Hirose, Y.; Kariya, K.; Sasaki, I.; Kurono, Y.; Ebiike, H.; Achiwa, K. Tetrahedron Lett. 1992, 33, 7157-7160. (c) For a recent review, see: Marchalín, S.; Chudík, M.; Mastihuba, V.; Decroix, B. Heterocycles 1998, 48, 1943-1958.
18. In the corresponding DHP series the application of biocatalytic methods in order to obtain enantiomerically pure derivatives is well established: (a) Holdgrün, X. K.; Sih, C. J. Tetrahedron Lett. 1991, 32, 3465-3468. (b) Hirose, Y.; Kariya, K.; Sasaki, I.; Kurono, Y.; Ebiike, H.; Achiwa, K. Tetrahedron Lett. 1992, 33, 7157-7160. (c) For a recent review, see: Marchalín, S.; Chudík, M.; Mastihuba, V.; Decroix, B. Heterocycles 1998, 48, 1943-1958.
19. In the corresponding DHP series the application of biocatalytic methods in order to obtain enantiomerically pure derivatives is well established: (a) Holdgrün, X. K.; Sih, C. J. Tetrahedron Lett. 1991, 32, 3465-3468. (b) Hirose, Y.; Kariya, K.; Sasaki, I.; Kurono, Y.; Ebiike, H.; Achiwa, K. Tetrahedron Lett. 1992, 33, 7157-7160. (c) For a recent review, see: Marchalín, S.; Chudík, M.; Mastihuba, V.; Decroix, B. Heterocycles 1998, 48, 1943-1958.
20. Kappe, C. O.; Falsone, F. S. Synlett 1998, 718-720.
21. Nagai, H.; Shiozawa, T.; Achiwa, K.; Terao, Y. Chem. Pharm. Bull. 1993, 41, 1933-1938.
22. de la Casa, R. M.; Sánchez-Montero, J. M.; Sinisterra, J. V. Biotechnol. Lett. 1999, 21, 123-128.
23. f=0.17, 88 mg, 99% yield, 96% ee). This protocol was peformed on a sixfold scale (1.20 g starting material) giving identical results. The amount of lipase can be significantly reduced; however, in this instance the reaction time is increased to ca. 5 d.
24. Alpegiani, M.; Bedeschi, A.; Giudici, F.; Perrone, E.; Visentin, G.; Zarini, F.; Franceschi, G. Heterocycles 1990, 30, 799-812.
25. D=-147.4 (c=1, MeOH)).
26. Krenn, W.; Verdino, P.; Uray, G.; Faber, K.; Kappe, C. O. Chirality 1999, 11, 659-662.